U.S. Markets open in 3 hrs 26 mins
  • S&P Futures

    4,541.75
    +33.25 (+0.74%)
     
  • Dow Futures

    34,313.00
    +311.00 (+0.91%)
     
  • Nasdaq Futures

    15,938.75
    +69.00 (+0.43%)
     
  • Russell 2000 Futures

    2,173.80
    +27.50 (+1.28%)
     
  • Crude Oil

    67.03
    +1.46 (+2.23%)
     
  • Gold

    1,776.30
    -8.00 (-0.45%)
     
  • Silver

    22.36
    +0.03 (+0.12%)
     
  • EUR/USD

    1.1342
    +0.0019 (+0.1701%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    28.11
    +0.92 (+3.38%)
     
  • GBP/USD

    1.3318
    +0.0040 (+0.3036%)
     
  • USD/JPY

    113.0220
    +0.2420 (+0.2146%)
     
  • BTC-USD

    56,585.61
    -411.88 (-0.72%)
     
  • CMC Crypto 200

    1,443.42
    -25.66 (-1.75%)
     
  • FTSE 100

    7,128.94
    -39.74 (-0.55%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET.

A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005089/en/

Contacts

PR Contact

Kristin Ainsworth
kainsworth@serestherapeutics.com

IR Contact

Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com